Compounds > fatostatin
Page last updated: 2024-11-09

fatostatin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

fatostatin: inhibits activation of SREBP; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1889993
CHEMBL ID1621019
CHEBI ID95052
SCHEMBL ID2742732
MeSH IDM0541890

Synonyms (35)

Synonym
AKOS005434229
2-propyl-4-(4-p-tolyl-thiazol-2-yl)-pyridine
smr000221636
MLS000332366 ,
OPREA1_120708
STK326446
4-[4-(4-methylphenyl)-1,3-thiazol-2-yl]-2-propylpyridine
4-(4-methylphenyl)-2-(2-propylpyridin-4-yl)-1,3-thiazole
CHEMBL1621019 ,
fatostatin
S9785
125256-00-0
ZROSUBKIGBSZCG-UHFFFAOYSA-N
4-(4-methylphenyl)-2-(2-propylpyridin-4-yl)-1,3-thiazole;hydrobromide
bdbm78179
cid_2850562
2-(2-propyl-4-pyridyl)-4-(p-tolyl)thiazole;hydrobromide
4-(4-methylphenyl)-2-(2-propyl-4-pyridinyl)thiazole;hydrobromide
SCHEMBL2742732
fatostatin a
AC-35652
2-(2-propyl-4-pyridyl)-4-(p-tolyl)thiazole
CS-5810
HY-14452
CHEBI:95052
2-(2-propylpyridin-4-yl)-4-(p-tolyl)thiazole ,
fatostatin;125b11
BCP20994
4-(4-methylphenyl)-2-(2-propyl-4-pyridinyl)thiazole
Q27166821
BS-15072
AMY41632
D84076
pyridine, 4-[4-(4-methylphenyl)-2-thiazolyl]-2-propyl-
4-(4-methylphenyl)-2-(2-propyl-4-pyridyl)-1,3-thiazole

Research Excerpts

Overview

Fatostatin is a small molecule that inhibits the maturation and function of SREBP. Its role in regulating inflammation is poorly understood.

ExcerptReferenceRelevance
"Fatostatin is a small molecule that inhibits the maturation and function of SREBP, and its role in regulating inflammation is poorly understood."( Fatostatin ameliorates inflammation without affecting cell viability.
Akizuki, S; Hashimoto, M; Kitagori, K; Ma, S; Mimori, T; Morinobu, A; Murakami, K; Nakashima, R; Ohmura, K; Tanaka, K; Tanaka, M; Yoshifuji, H, 2022)		2.89
"Fatostatin is a small molecule non-sterol diarylthiazole derivative that acts as a chemical inhibitor of the sterol regulatory-element binding protein (SREBP) pathway."( Fatostatin inhibits the development of endometrial carcinoma in endometrial carcinoma cells and a xenograft model by targeting lipid metabolism.
Chen, S; Li, W; Yao, L, 2020)		2.72
"Fatostatin is a chemical inhibitor of the SREBP pathway that directly binds SCAP and blocks its ER-to-Golgi transport."( Fatostatin blocks ER exit of SCAP but inhibits cell growth in a SCAP-independent manner.
Espenshade, PJ; Machamer, CE; Shao, W, 2016)		2.6

Actions

Fatostatin's ability to inhibit SREBP activity and cell division could prove beneficial in treating aggressive types of cancers such as glioblastomas that have elevated lipid metabolism and fast proliferation rates.

ExcerptReferenceRelevance
"Fatostatin inhibited the increase of both isoforms of SREBP (types 1 and 2) in diabetic kidneys."( Inhibition of SREBP With Fatostatin Does Not Attenuate Early Diabetic Nephropathy in Male Mice.
Gao, B; Ingram, AJ; Krepinsky, JC; Marway, M; Mehta, N; Parthasarathy, P; Van Krieken, R, 2018)		1.51
"Thus Fatostatin's ability to inhibit SREBP activity and cell division could prove beneficial in treating aggressive types of cancers such as glioblastomas that have elevated lipid metabolism and fast proliferation rates and often develop resistance to current anticancer therapies."( Fatostatin Inhibits Cancer Cell Proliferation by Affecting Mitotic Microtubule Spindle Assembly and Cell Division.
Bensinger, SJ; Cheung, K; Gholkar, AA; Hamideh, SA; Khuu, C; Lo, YC; Nnebe, C; Torres, JZ; Williams, KJ, 2016)		2.33

Compound-Compound Interactions

ExcerptReferenceRelevance
" These data suggest for the first time that fatostatin alone or in combination with docetaxel could be exploited as a novel and promising therapy for metastatic PCa harboring p53 mutations."( Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Chung, LW; Huang, WC; Li, X; Wu, JB, 2015)		0.68
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
thiazolesAn azole in which the five-membered heterocyclic aromatic skeleton contains a N atom and one S atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sterol regulatory element-binding protein 2Homo sapiens (human)IC50 (µMol)7.80000.30005.300010.0000AID615677; AID615679
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
positive regulation of cholesterol storageSterol regulatory element-binding protein 2Homo sapiens (human)
negative regulation of cholesterol effluxSterol regulatory element-binding protein 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISterol regulatory element-binding protein 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IISterol regulatory element-binding protein 2Homo sapiens (human)
lipid metabolic processSterol regulatory element-binding protein 2Homo sapiens (human)
cholesterol metabolic processSterol regulatory element-binding protein 2Homo sapiens (human)
regulation of Notch signaling pathwaySterol regulatory element-binding protein 2Homo sapiens (human)
cellular response to starvationSterol regulatory element-binding protein 2Homo sapiens (human)
SREBP signaling pathwaySterol regulatory element-binding protein 2Homo sapiens (human)
cholesterol homeostasisSterol regulatory element-binding protein 2Homo sapiens (human)
positive regulation of cholesterol biosynthetic processSterol regulatory element-binding protein 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISterol regulatory element-binding protein 2Homo sapiens (human)
cellular response to low-density lipoprotein particle stimulusSterol regulatory element-binding protein 2Homo sapiens (human)
cellular response to laminar fluid shear stressSterol regulatory element-binding protein 2Homo sapiens (human)
regulation of mitophagySterol regulatory element-binding protein 2Homo sapiens (human)
positive regulation of miRNA transcriptionSterol regulatory element-binding protein 2Homo sapiens (human)
positive regulation of protein targeting to mitochondrionSterol regulatory element-binding protein 2Homo sapiens (human)
positive regulation of cholesterol storageSterol regulatory element-binding protein 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
C-8 sterol isomerase activitySterol regulatory element-binding protein 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingSterol regulatory element-binding protein 2Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificSterol regulatory element-binding protein 2Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificSterol regulatory element-binding protein 2Homo sapiens (human)
protein bindingSterol regulatory element-binding protein 2Homo sapiens (human)
protein dimerization activitySterol regulatory element-binding protein 2Homo sapiens (human)
E-box bindingSterol regulatory element-binding protein 2Homo sapiens (human)
sequence-specific double-stranded DNA bindingSterol regulatory element-binding protein 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
Golgi membraneSterol regulatory element-binding protein 2Homo sapiens (human)
nucleusSterol regulatory element-binding protein 2Homo sapiens (human)
nucleoplasmSterol regulatory element-binding protein 2Homo sapiens (human)
cytoplasmSterol regulatory element-binding protein 2Homo sapiens (human)
endoplasmic reticulumSterol regulatory element-binding protein 2Homo sapiens (human)
endoplasmic reticulum membraneSterol regulatory element-binding protein 2Homo sapiens (human)
cytosolSterol regulatory element-binding protein 2Homo sapiens (human)
ER to Golgi transport vesicle membraneSterol regulatory element-binding protein 2Homo sapiens (human)
intracellular membrane-bounded organelleSterol regulatory element-binding protein 2Homo sapiens (human)
chromatinSterol regulatory element-binding protein 2Homo sapiens (human)
SREBP-SCAP-Insig complexSterol regulatory element-binding protein 2Homo sapiens (human)
nucleusSterol regulatory element-binding protein 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID1181169Antimicrobial activity against second mutant generation Mycobacterium tuberculosis 1024_18 assessed as fold shift in MIC relative to parent strain2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.
AID615770Metabolic stability in mouse hepatocytes at 1 uM after 90 mins by LC-MS/MS analysis2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Synthesis and evaluation of diarylthiazole derivatives that inhibit activation of sterol regulatory element-binding proteins.
AID1181168Antimicrobial activity against first mutant generation Mycobacterium tuberculosis 1024_18 assessed as fold shift in MIC relative to parent strain2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.
AID615766Aqueous solubility of the compound at pH 3 after 24 hrs by LC-MS/MS analysis2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Synthesis and evaluation of diarylthiazole derivatives that inhibit activation of sterol regulatory element-binding proteins.
AID1181170Antimicrobial activity against second mutant generation Mycobacterium tuberculosis 1024_8.12 assessed as fold shift in MIC relative to parent strain2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.
AID1181148Solubility of the compound2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.
AID1181171Antimicrobial activity against second mutant generation Mycobacterium tuberculosis 1024_16.5 assessed as fold shift in MIC relative to parent strain2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.
AID1181167Antimicrobial activity against first mutant generation Mycobacterium tuberculosis 1024_1 assessed as fold shift in MIC relative to parent strain2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.
AID615771Apparent permeability at 10 uM after 4 hrs by PAMPA2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Synthesis and evaluation of diarylthiazole derivatives that inhibit activation of sterol regulatory element-binding proteins.
AID615679Inhibition of SREBP2 activation expressed in CHO-K1 cells by densitometric analysis2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Synthesis and evaluation of diarylthiazole derivatives that inhibit activation of sterol regulatory element-binding proteins.
AID615769Half life in mouse hepatocytes at 1 uM after 90 mins by LC-MS/MS analysis2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Synthesis and evaluation of diarylthiazole derivatives that inhibit activation of sterol regulatory element-binding proteins.
AID1181176Antimicrobial activity against Mycobacterium tuberculosis H37Rv over-expressing InhA cells assessed as upshift of MIC relative to wild type2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.
AID615778Apparent permeability assessed as membrane retention at 10 uM after 4 hrs by PAMPA2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Synthesis and evaluation of diarylthiazole derivatives that inhibit activation of sterol regulatory element-binding proteins.
AID1181172Antimicrobial activity against second mutant generation Mycobacterium tuberculosis 1024_16.6 assessed as fold shift in MIC relative to parent strain2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.
AID615768Intrinsic clearance in mouse hepatocytes at 1 uM after 90 mins by LC-MS/MS analysis2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Synthesis and evaluation of diarylthiazole derivatives that inhibit activation of sterol regulatory element-binding proteins.
AID615677Inhibition of SREBP2 activation expressed in CHO-K1 cells co-transfected with pSRE-Luc plasmid assessed as inhibition of luciferase expression after 20 hrs by luciferase reporter gene assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Synthesis and evaluation of diarylthiazole derivatives that inhibit activation of sterol regulatory element-binding proteins.
AID1181147Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 5 days by microdilution method2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.
AID615767Aqueous solubility of the compound at pH 7 after 24 hrs by LC-MS/MS analysis2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Synthesis and evaluation of diarylthiazole derivatives that inhibit activation of sterol regulatory element-binding proteins.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (34)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (2.94)29.6817
2010's24 (70.59)24.3611
2020's9 (26.47)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.38 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index6.55 (4.65)
Search Engine Demand Index42.51 (26.88)
Search Engine Supply Index2.04 (0.95)

This Compound (35.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (5.88%)6.00%
Case Studies1 (2.94%)4.05%
Observational0 (0.00%)0.25%
Other31 (91.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
isoniazid
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).		2.110carbohydrazideantitubercular agent;
drug allergen
temozolomide
[no description available]		2.610imidazotetrazine;
monocarboxylic acid amide;
triazene derivative		alkylating agent;
antineoplastic agent;
prodrug
triclosan
[no description available]		2.110aromatic ether;
dichlorobenzene;
monochlorobenzenes;
phenols		antibacterial agent;
antimalarial;
drug allergen;
EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
fungicide;
persistent organic pollutant;
xenobiotic
quinazolines
Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.		2.1310azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
adamantane
Adamantane: A tricyclo bridged hydrocarbon.		3.1710adamantanes;
polycyclic alkane
thiazoles
[no description available]		6.493001,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
25-hydroxycholesterol
[no description available]		2.492025-hydroxy steroid;
oxysterol		human metabolite
masoprocol
Masoprocol: A potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to a lesser extent. It also serves as an antioxidant in fats and oils.. masoprocol : The meso-form of nordihydroguaiaretic acid. An antioxidant found in the creosote bush, Larrea divaricata, it is a potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. It also inhibits (though to a lesser extent) formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase.		2.1510nordihydroguaiaretic acidantineoplastic agent;
hypoglycemic agent;
lipoxygenase inhibitor;
metabolite
betulin
betulin: isolated from various white birch bark (BETULA). betulin : A pentacyclic triterpenoid that is lupane having a double bond at position 20(29) as well as 3beta-hydroxy and 28-hydroxymethyl substituents.		3.6220diol;
pentacyclic triterpenoid		analgesic;
anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
metabolite
gefitinib
[no description available]		2.1310aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
docetaxel anhydrous
Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.		2.1110secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
moxifloxacin
Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.		2.110aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug
angiotensin ii
Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).		2.1110amino acid zwitterion;
angiotensin II		human metabolite
metribolone
Metribolone: A synthetic non-aromatizable androgen and anabolic steroid. It binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors.. 17beta-hydroxy-17-methylestra-4,9,11-trien-3-one : A synthetic non-aromatisable androgen and anabolic steroid. It binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors.		2.11017beta-hydroxy steroid;
3-oxo steroid;
anabolic androgenic steroid		androgen
linezolid
[no description available]		2.110acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
t0901317
T0901317: an LXRalpha and LXRbeta agonist		2.5420
terameprocol
[no description available]		2.1510lignan
tamoxifen
[no description available]		7.7220stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
ethionamide
Ethionamide: A second-line antitubercular agent that inhibits mycolic acid synthesis.. ethionamide : A thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide.		2.110pyridines;
thiocarboxamide		antilipemic drug;
antitubercular agent;
fatty acid synthesis inhibitor;
leprostatic drug;
prodrug
adhesamine
adhesamine: synthetic diaryldispirotripiperazine that targets selective cell-surface glycosaminoglycans,especially heparan sulfate, for increasing cell adhesion and growth; a useful reagent for culturing neuronal cells		3.1710
chromeceptin
chromeceptin: inhibits Igf2 at the transcriptional level; structure in first source		3.1710
luteolin
[no description available]		2.17103'-hydroxyflavonoid;
tetrahydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist
bedaquiline
bedaquiline: a diarylquinoline Antitubercular Agent. bedaquiline : A quinoline-based antimycobacterial drug used (as its fumarate salt) for the treatment of pulmonary multi-drug resistant tuberculosis by inhibition of ATP synthase, an enzyme essential for the replication of the mycobacteria.		2.110aromatic ether;
naphthalenes;
organobromine compound;
quinolines;
tertiary alcohol;
tertiary amino compound		antitubercular agent;
ATP synthase inhibitor
adamanolol
adamanolol: structure in first source		3.1710
oligonucleotides
[no description available]		2.1110
pf-429242
PF-429242: a subtilisin kexin isozyme-1/site-1 protease inhibitor		2.5520
plx4032
[no description available]		2.1710aromatic ketone;
difluorobenzene;
monochlorobenzenes;
pyrrolopyridine;
sulfonamide		antineoplastic agent;
B-Raf inhibitor
minocycline
Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.		2.1710
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		2.0610benzenes;
hydroxycoumarin;
methyl ketone
epidermal growth factor
Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.		2.1710
transforming growth factor beta
Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.		2.1310
silybin
Silybin: The major active component of silymarin flavonoids extracted from seeds of the MILK THISTLE, Silybum marianum; it is used in the treatment of HEPATITIS; LIVER CIRRHOSIS; and CHEMICAL AND DRUG INDUCED LIVER INJURY, and has antineoplastic activity; silybins A and B are diastereomers.		2.110
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		2.110cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.4110
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		07.4110
Fatty Liver, Nonalcoholic
[description not available]		02.4110
Breast Cancer
[description not available]		07.7220
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.7220
Non-alcoholic Fatty Liver Disease
Fatty liver finding without excessive ALCOHOL CONSUMPTION.		02.4110
Benign Neoplasms, Brain
[description not available]		03.0120
Astrocytoma, Grade IV
[description not available]		03.0120
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		03.0120
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.		08.0120
Intraocular Pressure
The pressure of the fluids in the eye.		02.610
Cancer of Esophagus
[description not available]		02.2110
Esophageal Neoplasms
Tumors or cancer of the ESOPHAGUS.		02.2110
Cancer of Endometrium
[description not available]		02.9330
Endometrial Neoplasms
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.		02.9330
Carcinogenesis
The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Hepatocellular Carcinoma
[description not available]		02.2510
Cancer of Liver
[description not available]		02.2510
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.2510
Liver Neoplasms
Tumors or cancer of the LIVER.		02.2510
Experimental Mammary Neoplasms
[description not available]		02.2510
Endometrial Diseases
[description not available]		02.3110
Uterine Diseases
Pathological processes involving any part of the UTERUS.		02.3110
Cancer of Pancreas
[description not available]		02.1510
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		02.1510
Congenital Zika Syndrome
[description not available]		02.1510
Encephalitis, West Nile Fever
[description not available]		02.1510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.1510
West Nile Fever
A mosquito-borne viral illness caused by the WEST NILE VIRUS, a FLAVIVIRUS and endemic to regions of Africa, Asia, and Europe. Common clinical features include HEADACHE; FEVER; maculopapular rash; gastrointestinal symptoms; and lymphadenopathy. MENINGITIS; ENCEPHALITIS; and MYELITIS may also occur. The disease may occasionally be fatal or leave survivors with residual neurologic deficits. (From Joynt, Clinical Neurology, 1996, Ch26, p13; Lancet 1998 Sep 5;352(9130):767-71)		02.1510
Autoimmune Diabetes
[description not available]		02.1710
Diabetic Glomerulosclerosis
[description not available]		02.1710
Diabetes Mellitus, Type 1
A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.		02.1710
Diabetic Nephropathies
KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.		02.1710
Carcinoma, Non-Small Cell Lung
[description not available]		02.5520
Exanthem
[description not available]		02.1710
Cancer of Lung
[description not available]		02.5520
Paronychia
An inflammatory reaction involving the folds of the skin surrounding the fingernail. It is characterized by acute or chronic purulent, tender, and painful swellings of the tissues around the nail, caused by an abscess of the nail fold. The pathogenic yeast causing paronychia is most frequently Candida albicans. Saprophytic fungi may also be involved. The causative bacteria are usually Staphylococcus, Pseudomonas aeruginosa, or Streptococcus. (Andrews' Diseases of the Skin, 8th ed, p271)		02.1710
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		02.5520
Diarrhea
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.		02.1710
Exanthema
Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke's disease), fifth (ERYTHEMA INFECTIOSUM), and sixth (EXANTHEMA SUBITUM) numeric designations survive as occasional synonyms in current terminology.		02.1710
Lung Neoplasms
Tumors or cancer of the LUNG.		02.5520
Malignant Melanoma
[description not available]		02.1710
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		02.1710
Disease Exacerbation
[description not available]		02.1710
Nasopharyngeal Carcinoma
A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.		02.1710
Cancer of Nasopharynx
[description not available]		02.1710
Nasopharyngeal Neoplasms
Tumors or cancer of the NASOPHARYNX.		02.1710
Angiogenesis, Pathologic
[description not available]		02.110
Cancer of Prostate
[description not available]		02.7930
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.7930
Androgen-Independent Prostatic Cancer
[description not available]		02.110
Prostatic Neoplasms, Castration-Resistant
Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.		02.110
Chronic Kidney Diseases
[description not available]		02.1110
Cirrhosis
[description not available]		02.5220
Fibrosis
Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.		02.5220
Renal Insufficiency, Chronic
Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)		02.1110
Cardiometabolic Syndrome
A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.		03.0310
Metabolic Syndrome
A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.		03.0310
Hyper IgD Syndrome
[description not available]		02.1310
Mevalonate Kinase Deficiency
Autosomal recessive disorder caused by mutations in the mevalonate kinase gene. Because of the mutations cholesterol biosynthesis is disrupted and MEVALONIC ACID accumulates. It is characterized by a range of symptoms, including dysmorphic FACIES, psychomotor retardation, CATARACT, hepatosplenomegaly, CEREBELLAR ATAXIA, elevated IMMUNOGLOBULIN D, and recurrent febrile crises with FEVER; LYMPHADENOPATHY; ARTHRALGIA; EDEMA; and rash.		02.1310
Benign Neoplasms
[description not available]		02.1310
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.1310
Ureteral Obstruction
Blockage in any part of the URETER causing obstruction of urine flow from the kidney to the URINARY BLADDER. The obstruction may be congenital, acquired, unilateral, bilateral, complete, partial, acute, or chronic. Depending on the degree and duration of the obstruction, clinical features vary greatly such as HYDRONEPHROSIS and obstructive nephropathy.		02.1310
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		02.0510